Skip to main content

Table 6 Comparison of TTP and OS according to the clinical factors and genotypes

From: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

  

Time to progression

Overall survival

  

Median TTP (Mo)*

HR#

95% CI

p-value#

Median OS (Mo)*

HR#

95% CI

p-value#

Age

≤ 55

5.6

1.000

 

0.485

11.9

1.000

 

0.146

 

> 55

5.0

0.840

0.514–1.371

 

10.8

1.610

0.847–3.060

 

Performance

ECOG 0–1

6.0

1.000

 

0.042

12.6

1.000

 

0.124

 

ECOG 2

3.7

1.892

1.022–3.501

 

10.0

1.722

0.862–3.441

 

Histotype

Intestinal

6.1

1.000

 

0.495

14.5

1.000

 

0.392

 

Diffuse

5.6

1.197

0.714–2.009

 

10.8

1.337

0.687–2.602

 

Disease status

Initial stage IV

5.6

1.000

 

0.362

12.6

1.000

 

0.903

 

Relapsed

6.0

1.288

0.748–2.219

 

10.8

0.959

0.489–1.881

 

TS 5'UTR

2R/2R, 2R/3C, 3C/3C

5.6

1.000

 

0.781

10.8

1.000

 

0.244

 

2R/3G, 3C/3G, 3G/3G

6.1

0.781

0.415–1.470

 

17.4

0.669

0.340–1.316

 

TS 6-bp deletion in 3'UTR

+6/+6 or +6/-6

4.7

1.000

 

0.033

10.3

1.000

 

0.046

 

-6/-6

6.3

0.572

0.342–0.956

 

17.8

0.536

0.291–0.988

 

GSTP1-Ile105Val

A/A

6.0

1.000

 

0.398

11.9

1.000

 

0.621

 

A/G or G/G

6.3

1.243

0.750–2.061

 

14.5

0.621

0.452–1.606

 

ERCC-Asn118Asn

C/C

6.2

1.000

 

0.433

14.5

1.000

 

0.472

 

C/T or T/T

5.0

0.822

0.503–1.342

 

11.9

1.251

0.680–2.302

 

ERCC-C8092A

C/C

6.1

1.000

 

0.826

17.8

1.000

 

0.326

 

C/A or A/A

5.6

0.945

0.569–1.568

 

11.4

1.356

0.739–2.490

 

XPD- Arg156Arg

C/C

4.1

1.000

 

0.022

10.5

1.000

 

0.355

 

C/A or A/A

6.2

0.533

0.311–0.913

 

14.5

0.738

0.367–1.405

 

XPD-Asp312Asn

G/G

6.1

1.000

 

0.084

14.0

1.000

 

0.673

 

G/A

3.5

1.942

0.914–4.129

 

10.8

0.800

0.283–2.256

 

XPD-Lys751Gln

A/A

6.1

1.000

 

0.693

12.6

1.000

 

0.173

 

A/C or C/C

4.6

0.872

0.440–1.725

 

Not reached

0.488

0.174–1.369

 

XRCC1-Arg399Gln

G/G

6.1

1.000

 

0.744

15.3

1.000

 

0.160

 

G/A or A/A

5.9

1.090

0.649–1.832

 

10.3

1.575

0.835–2.971

 
  1. Mo, months; HR, hazard ratio; CI, confidence interval.
  2. * By Kaplan-Meier analysis
  3. #By Cox proportional hazard regression model, adjusted for performance
  4. Note: If the hazard ratio is greater than 1, the hazard ratio can be thought of as the average increased risk of progression, or death at any point in time, compared with the reference group (described above line).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us